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ABSTRACT
Introduction: The standard postsurgical
treatment of wounds after dermatologic
procedures is currently limited. Topical
corticosteroids have been used successfully in
postoperative management of ophthalmologic
surgeries that involve the skin of the eyelid. In
particular, tobramycin 0.3%/dexamethasone
0.1% ophthalmic ointment is considered
the ‘‘gold standard’’ of steroid-antibiotic fixed
combinations and is marketed worldwide as an
agent used to control postsurgical inflammation
and prevent postsurgical infection. The purpose
of this study is to evaluate both the efficacy and
safety of tobramycin–dexamethasone ointment
for the postsurgical management of Mohs or
dermatologic surgery in comparison to white
petrolatum.
Methods: The authors employed a half-scar
study in which patients who underwent skin
cancer removal surgery were given tobramycin–
dexamethasone ointment and white petrolatum
to apply to each half of their wound for 2 weeks.
The study was double blinded, and physicians
and the patients independently evaluated the
scars for cosmetic appearance at 2 and 6 weeks
postoperatively. The evaluation criteria included
judging which side of the wound looked better
based on color, thickness, and discomfort.
Results: Eighteen patients were enrolled, of
which 13 patients completed the three phases
of the study. After 6 weeks the wounds did not
show a statistically significant difference in
color, thickness, or discomfort on either side.
Conclusion: Results obtained to date suggest that
the application of tobramycin–dexamethasone
ointment to wounds after dermatologic surgery
does not promote better wound healing than
white petrolatum. These findings indicate that a
topical steroid and antibiotic ointment may not
be an effective intervention in improving
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postoperative outcomes in dermatologic
surgeries.
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INTRODUCTION
Aesthetically pleasing wound healing is a topic
of great interest. The success of a surgery is often
judged by the appearance of a scar, which may
lead to numerous cosmetic and psychological
consequences for the patient, including
anxiety, self-consciousness, and low self-
esteem [1]. Current recommendations for
postoperative wound care following Mohs and
other dermatological surgery include the
application of white petrolatum or a topical
antibiotic to the closed incision site before
covering the wound with a dressing in order
to create a moist healing environment [2, 3]. In
recent years, studies have questioned the
benefit of topical antibiotics in lieu of white
petrolatum in reducing the incidence of
postoperative wounds or leading to a more
positive cosmetic outcome [2]. In this study, we
sought to improve wound healing and reduce
infection and inflammation by applying a
tobramycin–dexamethasone ointment to the
wound postoperatively. We believed that the
combination of antimicrobial and anti-
inflammatory agents might serve to improve
the cosmetic appearance of the scars following
skin cancer removal surgery.
Tobramycin–dexamethasone is a sterile,
multiple dose antibiotic and steroid
combination, US Food and Drug Administration
approved for steroid-responsive inflammatory
ocular conditions for which a corticosteroid
is indicated and where the risk of bacterial
infection may exist. Between 2001 and 2006,
physicians prescribed over 16.3 million doses of
tobramycin–dexamethasone—more than any
other steroid/antibiotic ophthalmic combination
[4]. Tobramycin–dexamethasone is a widely used
empiric therapy for suspected eye infection, and
studies performed by Rhee and Mah [5]
demonstrated that it significantly decreases all
signs of ocular inflammation including
blepharitis, discharge, and conjunctivitis.
Tobramycin–dexamethasone has been found to
improve wound healing successfully after
ophthalmic surgeries by suppressing the
inflammatory response and protecting against
infection by susceptible strains of Gram-positive
and Gram-negative microorganisms [6].
In addition to its role in ocular and cataract
research, tobramycin–dexamethasone has
proved effective in reducing extracellular
matrix deposition in the treatment of external
and middle ear inflammation. In a study
performed with murine models, corticosteroids
effectively reduced the formation of
granulation tissue at the wound site [7]. The
amount of extracellular matrix components,
especially collagen, was decreased as were the
angiogenic factors that contributed to the blood
supply of the wound. The corticosteroid agent
inhibited the synthesis and processing
of multiple enzymes contributing to
inflammation, and in this manner effectively
reduced granulation tissue formation [7].
The purpose of this pilot study was to examine
whether tobramycin–dexamethasone ointment,
as both a corticosteroid and antimicrobial agent,
was more effective in promoting wound healing
than white petrolatum.
MATERIALS AND METHODS
The authors performed an institutional review
board approved, double blinded, randomized
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pilot study. Patients who had undergone skin
cancer removal surgery were recruited. The
investigation was designed as a half-scar study
similar to those that have been employed to test
the efficacy of other topical agents in promoting
wound healing [8].
Study Design
After completing surgery, the patients were given
two de-identified ointments, one of which was
white petrolatum, a common emollient, and the
other was the tobramycin–dexamethasone
combination ointment. Each ointment was
randomly labeled A or B. The postsurgery scars
were randomly divided into two halves, A and B,
distal and proximal or medial and lateral
depending on the position of the incision.
Patients were asked to put ointment A on side
A and ointment B on side B twice daily for
2 weeks, starting immediately after surgery.
The physicians and the patients
independently evaluated the scars for cosmetic
appearance on weeks 2 and 6. In this study, we
used a simplified version of the patient and
observer scar assessment scale (POSA) [9]. This
scar assessment scale, developed by Draaijers
et al. [9], takes into consideration both the
opinion of the patient and the physician when
considering wound healing. The observer scar
assessment scale evaluates a scar based on
vascularity, pigmentation, thickness, relief, and
pliability on a numerical rating scale from
1 (normal skin) to 10 (worst scar imaginable). The
patient scar assessment scale evaluated the scar
on the same scale, but based on pain, itching,
color, stiffness, thickness, and irregularity. The
opinions of the observer were shown to be
most affected by color (vascularization and
pigmentation) and thickness, whereas the
opinions of the patients were mainly influenced
by itching and thickness of the scar [9].
Although the POSA was developed for burn
scars specifically, further investigation has also
proved it a reliable method of evaluation for
linear scars [10]. We adapted the scale for our
small group of patients in our pilot study so that
the patients and observers evaluated the scar
based on the same parameters shown to be most
significant in the POSA: color, thickness, and
discomfort. The patients and observers then
made an overall judgment on which side of
their scar appeared ‘‘better,’’ while taking the
above said parameters into consideration.
After the patients’ and the observer’s
opinions were recorded, a third blinded
investigator was also shown photographs of
the outcomes, and his opinions were noted.
Data Analysis
As this is a pilot study, the analysis consists of
descriptive statistics. The results are presented as
a percentage of the total number of patients who
assessed their wounds as healing equally on both
sides, better on the tobramycin–dexamethasone
half, and better on the control half.
A total of 13 patients was included. The
demographic characteristics included seven
women and six men, with a mean age of
59 years (range 34–82 years). They consisted of
all non-Hispanic white adults. The scars were
located on the face (n = 2), neck (n = 2), chest
(n = 3), back (n = 1), arm (n = 3), and leg (n = 2).
The average scar length was approximately 4 cm,
which was deemed sufficient to perceive a
difference between the two halves. Data were
recorded as shown in the Appendix.
RESULTS
Twenty-four patients were assessed for
eligibility, six were excluded because they were
taking anticoagulants, 18 completed enrollment,
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and 13 completed the study with 6 weeks of
follow-up. Those who did not complete the
study withdrew on the day of surgery when they
were reminded of the study requirements, and
they reported that it was due to the added
inconvenience of applying more than one
ointment to their scar postoperatively.
No patients withdrew from the study after
receiving the two ointments. None of the
patients experienced adverse reactions to the
medications such as hypersensitivity and
localized toxicity, itching, swelling, and
erythema. Overall assessment at 2 weeks
demonstrated a relatively equal distribution
between the halves appearing equal, better on
the tobramycin–dexamethasone half, and
better on the white petrolatum half.
As seen in Fig. 1, when the patient’s
subjective opinion of the scar was procured,
approximately half of the patients deemed that
the scars had healed equally well on both sides
at 2 weeks. Observer 1 deemed that 69% of the
scars were equal, and observer 2 deemed that
there was an equal distribution between the
halves appearing equal, the tobramycin–
dexamethasone half appearing better, and the
control appearing better.
Figure 2 demonstrates that by 6 weeks
patients and observers found no perceivable
difference in the two halves of the scar in the
majority of cases. Sixty-two percent of patients
found no perceivable difference in the two
halves of their scar. According to both
observers, over 90% of the scars were deemed
identical on both sides. Overall, the results of
the study did not show that tobramycin–
dexamethasone ointment was more effective
in reducing erythema, scar thickness, or
discomfort than white petrolatum, nor did
tobramycin–dexamethasone lead to a more
attractive cosmetic outcome to the scar.
DISCUSSION
Both physicians and patients have employed a
variety of methods to improve wound healing,
including compression therapy, acrylic casts,
antihistamine drugs, silicone sheeting, and a
variety of topical creams [11]. The present study
was the first to our knowledge to compare the
effect of this particular steroid-antibiotic
combination to the current standard of care in
patients undergoing skin cancer removal
surgery. Although topical steroids and
antibiotics have been used successfully for
many types of skin care [2], our study did not
Fig. 1 The comparison of the scar halves at 2 weeks by
each evaluator
Fig. 2 The comparison of the scar halves at 6 weeks by
each evaluator
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indicate that a steroid-antibiotic agent
improved the cosmetic outcome of scars after
dermatologic surgery.
A limitation to the study was the small
sample size, as many of the patients screened
were excluded on the basis of their
anticoagulation medications. The results could
be confirmed by a larger study in a more diverse
group of subjects. Another limitation was
possible inaccuracy in the application of each
agent to its specified half of the scar. However,
this may not have impacted the outcome of the
study because the majority of the scars were
equal on each side, demonstrating that there
was no benefit of one agent over the other.
Corticosteroids have been shown to be
associated with impaired wound healing and
skin atrophy probably due to their inhibition of
collagen synthesis and degradation [12]. Topical
antibiotics have been associated with allergic
contact dermatitis and are known contributors
to antibiotic resistance [13].
In conclusion, a topically applied
corticosteroid and antibiotic combination did
not offer improved cosmesis and wound healing
when compared to petrolatum.
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APPENDIX
See Tables 1 and 2.
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